Y-mAbs Therapeutics (YMAB) Peer Comparison

$8.61

$0.00 (0.00%)

As on 16-Sep-2025 09:30EDT

Market cap

$391 Mln

Revenue (TTM)

$85 Mln

P/E Ratio

--

P/B Ratio

4.5

Div. Yield

0 %

Edit

	Y-mAbs Therapeutics (YMAB)	Hillevax Inc (HLVX)
Market cap ($ Mln)	391	105
Revenue ($ Mln)	85	--
Net Profit ($ Mln)	-22.22	-71.10
Net Margin (%)	-26.03	--
RoE (%)	-24.76	-47.04
Price to Earnings	--	--
Price-To-Book	4.47	0.71

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Y-mAbs Therapeutics (YMAB)	Hillevax Inc (HLVX)
Operating Revenue	85.39	0.00
Cost of Revenue	15.75	0.00
Gross Profit	72.43	--
Operating Expenses	96.23	77.12
Operating Profit (EBIT)	-26.65	-77.12
Other Income	0.00	0.00
Profit before Tax	-22.62	-71.10
Provision for Tax	-0.39	0.00
Profit after Tax (Net Income)	-22.22	-71.10
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	Y-mAbs Therapeutics (YMAB)	Hillevax Inc (HLVX)
Shareholder's Funds	87.49	147.82
Minority Interest	0.00	0.00
Non-Current Liabilities	6.77	20.95
Current Liabilities	22.95	6.15
Total Liabilities	119.90	192.69

Assets ($ Mln)

	Y-mAbs Therapeutics (YMAB)	Hillevax Inc (HLVX)
Non-Current Assets	25.42	12.67
Current Assets	91.79	162.24
Total Assets	119.90	192.69
Total Debt*	3.12	23.54
Net Current Assets	68.84	156.09

Cashflow ($ Mln)

	Y-mAbs Therapeutics (YMAB)	Hillevax Inc (HLVX)
Cash From Operating Activities	-15.71	-108.79
Cash Flow from Investing Activities	--	58.40
Cash from Financing Activities	4.31	-11.82
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Y-mAbs Therapeutics (YMAB)	Hillevax Inc (HLVX)
ROCE (%)	-30.39	-59.42
ROE (%)	-24.76	-47.04
ROA (%)	-13.56	-28.04
EBIT Margin (%)	-24.73	--
Net Margin (%)	-26.03	--
Cash Profit Margin (%)	0.00	--

Growth Ratios

	Y-mAbs Therapeutics (YMAB)	Hillevax Inc (HLVX)
Revenue Growth (%)	-1.34	--
EBIT Growth (%)	23.61	54.85
Net Profit Growth (%)	9.71	54.50
EPS Growth (%)	11.92	57.64
Book Value Growth (%)	-10.85	-29.21

Valuation Ratios

	Y-mAbs Therapeutics (YMAB)	Hillevax Inc (HLVX)
Price / Earnings	-11.84	-0.70
Price / Book Value	3.82	0.66
Dividend Yield (%)	--	--
EV/EBITDA	-9.29	0.29
Market Cap ($ Cr)	--	--

Solvency Ratios

	Y-mAbs Therapeutics (YMAB)	Hillevax Inc (HLVX)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	0.01	0.02
Current Ratio	4.00	26.39
Quick Ratio	3.58	26.39
Interest Coverage	--	-37.37

Operating Efficiency Ratios

	Y-mAbs Therapeutics (YMAB)	Hillevax Inc (HLVX)
Debtors to sales (%)	18.43	--
Asset Turnover	0.52	0.00
Receivable days	87.77	--
Inventory Days	147.04	--
Payable days	152.34	--
Cash Conversion Cycle	82.47	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly